On Mar. 17, 2020, Innovation Pharma announced details on the Material Transfer Agreement signed with a leading public health-focused U.S. university and top coronavirus expert.

Under the terms of the confidential agreement, virologists evaluated the potential antiviral properties of Brilacidin, the Company’s lead defensin-mimetic drug candidate, toward developing Brilacidin as a potential novel coronavirus (COVID-19) vaccine.